As the driver status of Her2, even in Her2-overexpressing or Her2-amplified bladder cancer cases, is difficult to predict without detailed genome-wide analyses [42], we propose the use of agents whose impact is independent of Her2-signaling inhibition. Here, ERBB2 is linked to urinary bladder cancer.